Brief: Edgewise Therapeutics Announces Positive 12-Month Topline Results From Arch Open Label Study Of EDG-5506 In Adults With Becker Muscular Dystrophy
26/06/2023 21:56
June 26 (Reuters) - Edgewise Therapeutics Inc EWTX.O :
* EDGEWISE THERAPEUTICS- ANNOUNCES POSITIVE 12-MONTH TOPLINE
RESULTS FROM ARCH OPEN LABEL STUDY OF EDG-5506 IN ADULTS WITH
BECKER MUSCULAR DYSTROPHY
* EDGEWISE THERAPEUTICS INC - EDG-5506 WAS WELL-TOLERATED AT
ALL
DOSES
* EDGEWISE THERAPEUTICS INC - CONTINUING TO ENROLL PATIENTS
WITH
BMD IN CANYON PHASE 2 TRIAL WHICH NOW INCLUDES A PIVOTAL COHORT
CALLED GRAND CANYON
Source text for Eikon: ID:nBwsFh34a
Further company coverage: EWTX.O
((Reuters.Brief@thomsonreuters.com;))
Recent news on Edgewise Therapeutics
See all newsBrief: Edgewise Therapeutics Doses First Patient In Phase 2 Equinox-Hfpef Trial Of Edg-15400
Edgewise Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Edgewise Therapeutics Q2 net loss widens on higher expenses
Brief: Edgewise Therapeutics Q2 Operating Income USD -61.943 Million
U.S. STOCKS ON THE MOVE-RBB Bancorp, Roblox, Open Lending